Receptor, fibroblast growth factor, type 3

Clinical trials for Receptor, fibroblast growth factor, type 3 explained in plain language.

Never miss a new study

Get alerted when new Receptor, fibroblast growth factor, type 3 trials appear

Sign up with your email to follow new studies for Receptor, fibroblast growth factor, type 3, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet recruiting 1

A pill instead of surgery? trial tests vepugratinib against Low-Grade bladder cancer

Disease control Not yet recruiting

Researchers are testing whether an oral drug called vepugratinib can clear low-grade, intermediate-risk bladder cancer that has not invaded muscle, or low-grade upper tract urothelial cancer. The trial enrolls adults whose tumors carry a specific change in the FGFR3 gene. Partici…

Matched conditions: RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 3

Phase 2 • Sponsor: Eli Lilly and Company • Aim: Disease control

Last updated Sep 20, 2026 00:00 UTC

Receptor, fibroblast growth factor, type 3

Get alerted when new Receptor, fibroblast growth factor, type 3 trials appear

A pill instead of surgery? trial tests vepugratinib against Low-Grade bladder cancer